Ultragenyx Pharmaceutical Inc. (RARE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Show:
Annual
Cash Flow
All numbers in thousandsBreakdown
ttm
2023-12-31
2022-12-31
2021-12-31
2020-12-31
Cash flows from operating activities
Net Income
-613,351
-606,639
-707,421
-454,025
-186,566
Depreciation & amortization
29,615
26,006
18,220
13,239
12,261
Stock based compensation
140,201
135,227
130,377
104,952
85,735
Change in working capital
-32,756
-15,101
60,235
-63,236
104,663
Accounts receivable
-45,178
-22,778
-12,068
-5,432
9,840
Inventory
-9,204
-6,930
-9,701
-3,117
-1,346
Accounts Payable
-
-
87,442
32,313
-
Other working capital
-543,610
-521,573
-526,588
-411,788
-176,125
Other non-cash items
-14,294
-1,060
96,126
11,706
21,242
Net cash provided by operating activites
-508,666
-474,806
-380,465
-338,695
-132,220
Cash flows from investing activities
Investments in property, plant and equipment
-34,944
-46,767
-146,123
-73,093
-43,905
Acquisitions, net
-
0
-75,025
0
-
Purchases of investments
-486,286
-526,382
-614,735
-1,012,187
-850,299
Sales/Maturities of investments
675,523
746,197
545,075
890,850
720,638
Other investing activites
-3,162
-5,048
-844
-942
-5,555
Net cash used for investing activites
151,131
168,000
-291,652
-195,372
-179,121
Cash flows from financing activities
Debt repayment
-33
-
-
-
-
Common stock issued
-
379,755
0
78,943
511,215
Other financing activites
-
-28
490,395
-492
-236
Net cash used privided by (used for) financing activities
388,806
388,142
501,208
118,552
600,272
Net change in cash
30,843
81,798
-171,984
-416,709
290,050
Cash at beginning of period
91,527
137,601
309,585
726,294
436,244
Cash at end of period
122,798
219,399
137,601
309,585
726,294
Free Cash Flow
Operating Cash Flow
-508,666
-474,806
-380,465
-338,695
-132,220
Capital Expenditure
-34,944
-46,767
-146,123
-73,093
-43,905
Free Cash Flow
-543,610
-521,573
-526,588
-411,788
-176,125
© 2024 Yahoo. All rights reserved.